Use of RNA interference to minimize ischemia reperfusion injury

Transplantation Reviews

Volumn 26, Issue 2, 2012, Pages 140-155

  Zhang, Zhu Xu ^a,b   Min, Wei ping ^a,b   Jevnikar, Anthony M ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; COMPLEMENT FACTOR; DICER; DOUBLE STRANDED RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P53; RIBOZYME; SINGLE STRANDED RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BLEEDING; CELL DEATH; CELL FUNCTION; CODON; DELAYED GRAFT FUNCTION; DNA SEQUENCE; DOWN REGULATION; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; HEART; HUMAN; INNATE IMMUNITY; ISCHEMIA; KIDNEY; LIVER; LUNG; MEDICAL FEE; NERVE CELL; NONHUMAN; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; REPERFUSION INJURY; REVIEW; RIBOZYME THERAPY; RNA INTERFERENCE; RNA SEQUENCE; RNA SYNTHESIS; SIGNAL TRANSDUCTION; TISSUE INJURY; VASCULARIZATION;

EID: 84859007413     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2011.03.001     Document Type: Review

References (214)

1. Coulson M.T., Jablonski P., Howden B.O., Thomson N.M., Stein A.N. Beyond operational tolerance: effect of ischemic injury on development of chronic damage in renal grafts. Transplantation 2005, 80:353-361.
2. Kouwenhoven E.A., de Bruin R.W., Bajema I.M., Marquet R.L., Ijzermans J.N. Cold ischemia augments allogeneic-mediated injury in rat kidney allografts. Kidney Int 2001, 59:1142-1148.
3. Knight R.J., Dikman S., Liu H., Martinelli G.P. Cold ischemic injury accelerates the progression to chronic rejection in a rat cardiac allograft model. Transplantation 1997, 64:1102-1107.
4. Schmid C., Heemann U., Tilney N.L. Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation. Transplantation 1997, 64:222-228.
5. Boros P., Bromberg J.S. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006, 6:652-658.
6. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270:1189-1192.
7. Sauter B., Albert M.L., Francisco L., et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000, 191:423-434.
8. Moers C., Smits J.M., Maathuis M.J., et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009, 360:7-19.
9. Gluba A., Banach M., Hannam S., et al. The role of toll-like receptors in renal diseases. Nat Rev Nephrol 2010, 6:224-235.
10. Bouma H.R., Ploeg R.J., Schuurs T.A. Signal transduction pathways involved in brain death-induced renal injury. Am J Transplant 2009, 9:989-997.
11. Izant J.G., Weintraub H. Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell 1984, 36:1007-1015.
12. Rosenberg U.B., Preiss A., Seifert E., Jäckle H., Knipple D.C. Production of phenocopies by Krüppel antisense RNA injection into Drosophila embryos. Nature 1985, 313:703-706.
13. Ecker J.R., Davis R.W. Inhibition of gene expression in plant cells by expression of antisense RNA. Proc Natl Acad Sci U S A 1986, 83:5372-5376.
14. Izant J.G., Weintraub H. Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science 1985, 229:345-352.
15. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
16. Fire A., Xu S., Montgomery M.K., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
17. Elbashir S.M., Harborth J., Lendeckel W., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
18. Saunders L.R., Barber G.N. The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J 2003, 17:961-983.
19. Tuschl T. Expanding small RNA interference. Nat Biotechnol 2002, 20:446-448.
20. Adah S.A., Bayly S.F., Cramer H., Silverman R.H., Torrence P.F. Chemistry and biochemistry of 2',5'-oligoadenylate-based antisense strategy. Curr Med Chem 2001, 8:1189-1212.
21. Williams B.R. Signal integration via PKR. Sci STKE 2001, re2:1-10.
22. Schlee M., Hornung V., Hartmann G. siRNA and isRNA: two edges of one sword. Mol Ther 2006, 14:463-470.
23. Timmons L. The long and short of siRNAs. Mol Cell 2002, 10:435-437.
24. Bartlett D.W., Davis M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 2006, 34:322-333.
25. Mehrabi A., Mood Z.A., Sadeghi M., et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant 2007, 22(Suppl 8):viii54-viii60.
26. Nigam A., Kopecky S.L. Therapeutic potential of monoclonal antibodies in myocardial reperfusion injury. Am J Cardiovasc Drugs 2002, 2:367-376.
27. Yeh W.C., Itie A., Elia A.J., et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000, 12:633-642.
28. Lebedeva I., Stein C.A. Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol 2001, 41:403-419.
29. Tong A.W., Zhang Y., Nemunaitis J. Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 2005, 7:114-124.
30. Bertrand J., Pottier M., Vekris A., et al. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002, 296:1000-1004.
31. Thompson J.D. Applications of antisense and siRNAs during preclinical drug development. Drug Discov Today 2002, 7:912-917.
32. Senn C., Hangartner C., Moes S., Guerini D., Hofbauer K.G. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides. Eur J Pharmacol 2005, 522:30-37.
33. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294:862-864.
34. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294:858-862.
35. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
36. Lim L.P., Lau N.C., Garrett-Engele P., et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
37. Baek D., Villén J., Shin C., et al. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
38. Hendrickson D.G., Hogan D.J., McCullough H.L., et al. Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol 2009, 7:e1000238.
39. Scherer L.J., Rossi J.J. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 2003, 21:1457-1465.
40. Cameron F.H., Jennings P.A. Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci U S A 1989, 86:9139-9143.
41. Haseloff J., Gerlach W.L., Simple R.N.A. enzymes with new and highly specific endoribonuclease activities. 1988. Biotechnology 1992, 24:264-269.
42. McCall M.J., Hendry P., Jennings P.A. Minimal sequence requirements for ribozyme activity. Proc Natl Acad Sci U S A 1992, 89:5710-5714.
43. Celotto A.M., Lee J., Graveley B.R. Exon-specific RNA interference: a tool to determine the functional relevance of proteins encoded by alternatively spliced mRNAs. Methods Mol Biol 2005, 309:273-282.
44. Grishok A., Tabara H., Mello C.C. Genetic requirements for inheritance of RNAi in C. elegans. Science 2000, 287:2494-2497.
45. Devroe E., Silver P.A. Retrovirus-delivered siRNA. BMC Biotechnol 2002, 2:15.
46. Zheng X., Vladau C., Zhang X., et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 2009, 113:2646-2654.
47. Elbashir S.M., Lendeckel W., Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001, 15:188-200.
48. Reynolds A., Leake D., Boese Q., et al. Rational siRNA design for RNA interference. Nat Biotechnol 2004, 22:326-330.
49. Whither RNAi?. Nat Cell Biol 2003, 5:489-490.
50. Naito M., Zager R.A., Bomsztyk K. BRG1 increases transcription of proinflammatory genes in renal ischemia. J Am Soc Nephrol 2009, 20:1787-1796.
51. Walton S.P., Wu M., Gredell J.A., Chan C. Designing highly active siRNAs for therapeutic applications. FEBS J 2010, 277:4806-4813.
52. Elbashir S.M., Martinez J., Patkaniowska A., Lendeckel W., Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001, 20:6877-6888.
53. Caplen N.J., Mousses S., Short interfering R.N.A. (siRNA)-mediated RNA interference (RNAi) in human cells. Ann N Y Acad Sci 2003, 1002:56-62.
54. Dykxhoorn D.M., Novina C.D., Sharp P.A. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003, 4:457-467.
55. Tiscornia G., Singer O., Ikawa M., Verma I.M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A 2003, 100:1844-1848.
56. Czauderna F., Fechtner M., Dames S., et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003, 31:2705-2716.
57. Kubo T., Zhelev Z., Ohba H., Bakalova R. Chemically modified symmetric and asymmetric duplex RNAs: an enhanced stability to nuclease degradation and gene silencing effect. Biochem Biophys Res Commun 2008, 365:54-61.
58. Kraynack B.A., Baker B.F. Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA 2006, 12:163-176.
59. Choung S., Kim Y.J., Kim S., Park H., Choi Y. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 2006, 342:919-927.
60. Allerson C.R., Sioufi N., Jarres R., et al. Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 2005, 48:901-904.
61. Chernolovskaya E.L., Zenkova M.A. Chemical modification of siRNA. Curr Opin Mol Ther 2010, 12:158-167.
62. Amarasinghe A.K., Calin-Jageman I., Harmouch A., Sun W., Nicholson A.W. Escherichia coli ribonuclease III: affinity purification of hexahistidine-tagged enzyme and assays for substrate binding and cleavage. Methods Enzymol 2001, 342:143-158.
63. Kim D., Longo M., Han Y., et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004, 22:321-325.
64. Czauderna F., Santel A., Hinz M., et al. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 2003, 31:e127.
65. Rossi J.J. Expression strategies for short hairpin RNA interference triggers. Hum Gene Ther 2008, 19:313-317.
66. Wadhwa R., Kaul S.C., Miyagishi M., Taira K. Vectors for RNA interference. Curr Opin Mol Ther 2004, 6:367-372.
67. Grimm D., Streetz K.L., Jopling C.L., et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441:537-541.
68. Matsukura S., Jones P.A., Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 2003, 31:e77.
69. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
70. Schwarz D.S., Hutvágner G., Du T., et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003, 115:199-208.
71. McCaffrey A.P., Meuse L., Pham T.T., et al. RNA interference in adult mice. Nature 2002, 418:38-39.
72. Zheng X., Lian D., Wong A., et al. Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation 2009, 120:1099-1107. [1 p following 1107].
73. Foged C., Nielsen H.M., Frokjaer S. Phospholipase A2 sensitive liposomes for delivery of small interfering RNA (siRNA). J Liposome Res 2007, 17:191-196.
74. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 2006, 8:343-375.
75. Soutschek J., Akinc A., Bramlage B., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
76. Kim S.H., Jeong J.H., Kim T., Kim S.W., Bull D.A. VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm 2009, 6:718-726.
77. Grimm D., Kay M.A. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 2006, 13:563-575.
78. Xia H., Mao Q., Paulson H.L., Davidson B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002, 20:1006-1010.
79. Rubinson D.A., Dillon C.P., Kwiatkowski A.V., et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003, 33:401-406.
80. Morris K.V., Rossi J.J. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther 2006, 13:553-558.
81. Bos T.J., De Bruyne E., Heirman C., Vanderkerken K. In search of the most suitable lentiviral shRNA system. Curr Gene Ther 2009, 9:192-211.
82. Zheng X., Koropatnick J., Li M., et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol 2006, 177:5639-5646.
83. de Jonge J., Holtrop M., Wilschut J., Huckriede A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther 2006, 13:400-411.
84. Kimchi-Sarfaty C., Brittain S., Garfield S., et al. Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions. Hum Gene Ther 2005, 16:1110-1115.
85. Yi Y., Hahm S.H., Lee K.H. Retroviral gene therapy: safety issues and possible solutions. Curr Gene Ther 2005, 5:25-35.
86. Bitko V., Musiyenko A., Shulyayeva O., Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005, 11:50-55.
87. Zhang X., Shan P., Jiang D., et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 2004, 279:10677-10684.
88. Shim M.S., Kwon Y.J. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010, 277:4814-4827.
89. Yang B., Hosgood S.A., Nicholson M.L. Naked small interfering RNA of caspase-3 in preservation solution and autologous blood perfusate protects isolated ischemic porcine kidneys. Transplantation 2011, 91:501-507.
90. Ma Z., Li J., He F., et al. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun 2005, 330:755-759.
91. Sioud M., Furset G., Cekaite L. Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. Biochem Biophys Res Commun 2007, 361:122-126.
92. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010, 9:57-67.
93. Scacheri P.C., Rozenblatt-Rosen O., Caplen N.J., et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A 2004, 101:1892-1897.
94. Kleinman M.E., Yamada K., Takeda A., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452:591-597.
95. Bramsen J.B., Laursen M.B., Damgaard C.K., et al. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007, 35:5886-5897.
96. Chen P.Y., Weinmann L., Gaidatzis D., et al. Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008, 14:263-274.
97. Jackson A.L., Burchard J., Leake D., et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12:1197-1205.
98. Ui-Tei K., Naito Y., Zenno S., et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008, 36:2136-2151.
99. Lu J.J., Langer R., Chen J. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol Pharm 2009, 6:763-771.
100. Wolfrum C., Shi S., Jayaprakash K.N., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007, 25:1149-1157.
101. Nishina K., Unno T., Uno Y., et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 2008, 16:734-740.
102. Eguchi A., Meade B.R., Chang Y., et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009, 27:567-571.
103. Muratovska A., Eccles M.R. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004, 558:63-68.
104. Dassie J.P., Liu X., Thomas G.S., et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009, 27:839-849.
105. McNamara J.O., Andrechek E.R., Wang Y., et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006, 24:1005-1015.
106. Zhou J., Swiderski P., Li H., et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 2009, 37:3094-3109.
107. Song E., Zhu P., Lee S., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005, 23:709-717.
108. Kumar P., Ban H., Kim S., et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134:577-586.
109. Chapman J.R., O'Connell P.J., Nankivell B.J. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005, 16:3015-3026.
110. Furukawa Y., Libby P., Stinn J.L., Becker G., Mitchell R.N. Cold ischemia induces isograft arteriopathy, but does not augment allograft arteriopathy in non-immunosuppressed hosts. Am J Pathol 2002, 160:1077-1087.
111. Akhtar S., Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. JClin Invest 2007, 117:3623-3632.
112. Imamura R., Isaka Y., Sandoval R.M., et al. Intravital 2-photon microscopy assessment of renal protection efficacy of siRNA for p53 in experimental rat kidney transplantation models. Cell Transplant 2010, 19:1659-1670.
113. Singaravelu K., Devalaraja-Narashimha K., Lastovica B., Padanilam B.J. PERP, a p53 proapoptotic target, mediates apoptotic cell death in renal ischemia. Am J Physiol Renal Physiol 2009, 296:F847-F858.
114. Daemen M.A.R.C., de Vries B., Buurman W.A. Apoptosis and inflammation in renal reperfusion injury. Transplantation 2002, 73:1693-1700.
115. Hutchings A., Wu J., Asiedu C., et al. The immune decision toward allograft tolerance in non-human primates requires early inhibition of innate immunity and induction of immune regulation. Transpl Immunol 2003, 11:335-344.
116. Sanz A.B., Sanchez-Niño M.D., Ramos A.M., et al. NF-kappaB in renal inflammation. J Am Soc Nephrol 2010, 21:1254-1262.
117. Feng B., Chen G., Zheng X., et al. Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury. Transplantation 2009, 87:1283-1289.
118. Sanz A.B., Sanchez-Niño M.D., Izquierdo M.C., et al. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS ONE 2010, 5:e8955.
119. Schmitt R., Marlier A., Cantley L.G. Zag expression during aging suppresses proliferation after kidney injury. J Am Soc Nephrol 2008, 19:2375-2383.
120. Molitoris B.A., Sutton T.A. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 2004, 66:496-499.
121. Hamar P., Song E., Kökény G., et al. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2004, 101:14883-14888.
122. Du C., Guan Q., Diao H., Yin Z., Jevnikar A.M. Nitric oxide induces apoptosis in renal tubular epithelial cells through activation of caspase-8. Am J Physiol Renal Physiol 2006, 290:F1044-F1054.
123. Brooks C., Wei Q., Cho S., Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. JClin Invest 2009, 119:1275-1285.
124. Zheng X., Zhang X., Sun H., et al. Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation 2006, 82:1781-1786.
125. Zhang X., Zheng X., Sun H., et al. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation 2006, 82:1728-1732.
126. Ben Mkaddem S., Pedruzzi E., Werts C., et al. Heat shock protein gp96 and NAD(P)H oxidase 4 play key roles in toll-like receptor 4-activated apoptosis during renal ischemia/reperfusion injury. Cell Death Differ 2010, 17:1474-1485.
127. Banas M.C., Banas B., Hudkins K.L., et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 2008, 19:704-713.
128. Hung C., Chang C., Chen K., et al. Upregulation of chemokine CXCL1/KC by leptospiral membrane lipoprotein preparation in renal tubule epithelial cells. Kidney Int 2006, 69:1814-1822.
129. Mkaddem S.B., Werts C., Goujon J., et al. Heat shock protein gp96 interactswith protein phosphatase 5 and controls toll-like receptor 2 (TLR2)-mediated activation of extracellular signal-regulated kinase (ERK) 1/2 in post-hypoxic kidney cells. J Biol Chem 2009, 284:12541-12549.
130. Arumugam T.V., Shiels I.A., Strachan A.J., et al. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 2003, 63:134-142.
131. Zheng X., Zhang X., Feng B., et al. Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol 2008, 173:973-980.
132. Zheng X., Feng B., Chen G., et al. Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant 2006, 6:2099-2108.
133. Sun B., Lu C., Zhou G., Xing C. Suppression of Par-4 protects human renal proximal tubule cells from apoptosis induced by oxidative stress. Nephron Exp Nephrol 2010, 117:e53-e61.
134. Glasgow S.C., Ramachandran S., Blackwell T.S., Mohanakumar T., Chapman W.C. Interleukin-1beta is the primary initiator of pulmonary inflammation following liver injury in mice. Am J Physiol Lung Cell Mol Physiol 2007, 293:L491-L496.
135. Song E., Lee S., Wang J., et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003, 9:347-351.
136. Li X., Zhang J.F., Lu M.Q., et al. Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas. Langenbecks Arch Surg 2007, 392:345-351.
137. Contreras J.L., Vilatoba M., Eckstein C., et al. Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice. Surgery 2004, 136:390-400.
138. Llacuna L., Marí M., Garcia-Ruiz C., Fernandez-Checa J.C., Morales A. Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. Hepatology 2006, 44:561-572.
139. Massip-Salcedo M., Zaouali M.A., Padrissa-Altés S., et al. Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion. Hepatology 2008, 47:461-472.
140. Kim M., Seo E.J., Lee D.H., et al. Gadd45beta is a novel mediator of cardiomyocyte apoptosis induced by ischaemia/hypoxia. Cardiovasc Res 2010, 87:119-126.
141. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
142. Wang Y., Wysocka J., Perlin J.R., et al. Linking covalent histone modifications to epigenetics: the rigidity and plasticity of the marks. Cold Spring Harb Symp Quant Biol 2004, 69:161-169.
143. Granger A., Abdullah I., Huebner F., et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 2008, 22:3549-3560.
144. Zhang Z., Deb A., Zhang Z., et al. Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. J Mol Cell Cardiol 2009, 46:370-377.
145. Ngoh G.A., Facundo H.T., Hamid T., et al. Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia/reoxygenation injury. Circ Res 2009, 104:41-49.
146. Natarajan R., Salloum F.N., Fisher B.J., Kukreja R.C., Fowler A.A. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res 2006, 98:133-140.
147. Song H., Zhang Z., Wang L. Small interference RNA against PTP-1B reduces hypoxia/reoxygenation induced apoptosis of rat cardiomyocytes. Apoptosis 2008, 13:383-393.
148. Kumar S., Kasseckert S., Kostin S., et al. Ischemic acidosis causes apoptosis in coronary endothelial cells through activation of caspase-12. Cardiovasc Res 2007, 73:172-180.
149. Kato M., Akao M., Matsumoto-Ida M., et al. The targeting of cyclophilin D by RNAi as a novel cardioprotective therapy: evidence from two-photon imaging. Cardiovasc Res 2009, 83:335-344.
150. Guo Z., Jiao Q., Wang S., Xu M., Gao F. Effect of ryanodine receptor 2 gene silencing on ischemia-reperfusion injury of rat myocardial cells. Zhonghua Bing Li Xue Za Zhi 2008, 37:760-764.
151. Natarajan R., Salloum F.N., Fisher B.J., et al. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol 2007, 293:H1571-H1580.
152. Singleton P.A., Pendyala S., Gorshkova I.A., et al. Dynamin 2 and c-Abl are novel regulators of hyperoxia-mediated NADPH oxidase activation and reactive oxygen species production in caveolin-enriched microdomains of the endothelium. J Biol Chem 2009, 284:34964-34975.
153. Chen C., Hu Q., Yan J., et al. Early inhibition of HIF-1alpha with small interfering RNA reduces ischemic-reperfused brain injury in rats. Neurobiol Dis 2009, 33:509-517.
154. Hu Q., Chen C., Khatibi N.H., et al. Lentivirus-mediated transfer of MMP-9 shRNA provides neuroprotection following focal ischemic brain injury in rats. Brain Res 2011, 1367:347-359.
155. Bevers M.B., Ingleton L.P., Che D., et al. RNAi targeting micro-calpain increases neuron survival and preserves hippocampal function after global brain ischemia. Exp Neurol 2010, 224:170-177.
156. Cao G., Xing J., Xiao X., et al. Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. JNeurosci 2007, 27:9278-9293.
157. Guo G., Bhat N.R. p38alpha MAP kinase mediates hypoxia-induced motor neuron cell death: a potential target of minocycline's neuroprotective action. Neurochem Res 2007, 32:2160-2166.
158. + exchanger isoform 1. Ann N Y Acad Sci 2007, 1099:292-305.
159. Dagher P.C. Apoptosis in ischemic renal injury: roles of GTP depletion and p53. Kidney Int 2004, 66:506-509.
160. Fraker P.J., King L.E., Lill-Elghanian D., Telford W.G. Quantification of apoptotic events in pure and heterogeneous populations of cells using the flow cytometer. Methods Cell Biol 1995, 46:57-76.
161. Molitoris B.A., Dagher P.C., Sandoval RM, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009, 20:1754-1764.
162. Bonventre J.V. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003, 14(Suppl 1):S55-S61.
163. Nogae S., Miyazaki M., Kobayashi N., et al. Induction of apoptosis in ischemia-reperfusion model of mouse kidney: possible involvement of Fas. J Am Soc Nephrol 1998, 9:620-631.
164. Du C., Guan Q., Yin Z., et al. Renal tubular epithelial cell apoptosis by Fas-FasL-dependent self-injury can augment renal allograft injury. Transplant Proc 2003, 35:2481-2482.
165. Daemen M.A., van de Ven M.W., Heineman E., Buurman W.A. Involvement of endogenous interleukin-10 and tumor necrosis factor-alpha in renal ischemia-reperfusion injury. Transplantation 1999, 67:792-800.
166. Donnahoo K.K., Shames B.D., Harken A.H., Meldrum D.R. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999, 162:196-203.
167. Dong X., Swaminathan S., Bachman L.A., et al. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 2007, 71:619-628.
168. Du C., Wang S., Diao H., et al. Increasing resistance of tubular epithelial cells to apoptosis by shRNA therapy ameliorates renal ischemia-reperfusion injury. Am J Transplant 2006, 6:2256-2267.
169. Zhou W., Farrar C.A., Abe K., et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000, 105:1363-1371.
170. de Vries B., Köhl J., Leclercq W.K.G., et al. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003, 170:3883-3889.
171. Puri T.S., Quigg R.J. The many effects of complement C3- and C5-binding proteins in renal injury. Semin Nephrol 2007, 27:321-337.
172. Yamada K., Miwa T., Liu J., Nangaku M., Song W. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. JImmunol 2004, 172:3869-3875.
173. Toledo-Pereyra L.H., Lopez-Neblina F., Toledo A.H. Reactive oxygen species and molecular biology of ischemia/reperfusion. Ann Transplant 2004, 9:81-83.
174. Millar T.M., Phan V., Tibbles L.A. ROS generation in endothelial hypoxia and reoxygenation stimulates MAP kinase signaling and kinase-dependent neutrophil recruitment. Free Radic Biol Med 2007, 42:1165-1177.
175. Cassie S., Masterson M.F., Polukoshko A., Viskovic M.M., Tibbles L.A. Ischemia/reperfusion induces the recruitment of leukocytes from whole blood under flow conditions. Free Radic Biol Med 2004, 36:1102-1111.
176. Matsumoto T., O'Malley K., Efron P.A., et al. Interleukin-6 and STAT3 protect the liver from hepatic ischemia and reperfusion injury during ischemic preconditioning. Surgery 2006, 140:793-802.
177. Lynn E.G., Stevens M.V., Wong R.P., et al. Transient upregulation of PGC-1alpha diminishes cardiac ischemia tolerance via upregulation of ANT1. J Mol Cell Cardiol 2010, 49:693-698.
178. Fischle W., Wang Y., Allis C.D. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003, 15:172-183.
179. Mirotsou M., Zhang Z., Deb A., et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A 2007, 104:1643-1648.
180. Torres C.R., Hart G.W. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem 1984, 259:3308-3317.
181. Zachara N.E., O'Donnell N., Cheung W.D., et al. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J Biol Chem 2004, 279:30133-30142.
182. Eschenhagen T. Is ryanodine receptor phosphorylation key to the fight or flight response and heart failure. J Clin Invest 2010, 120:4197-4203.
183. Guo Z., Wang S., Jiao Q., Xu M., Gao F. RNAi targeting ryanodine receptor 2 protects rat cardiomyocytes from injury caused by simulated ischemia-reperfusion. Biomed Pharmacother 2010, 64:184-190.
184. El-Achkar T.M., Wu X., Rauchman M., et al. Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Renal Physiol 2008, 295:F534-F544.
185. Jiang D., Liang J., Fan J., et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med 2005, 11:1173-1179.
186. Johnsson C., Tufveson G., Wahlberg J., Hällgren R. Experimentally-induced warm renal ischemia induces cortical accumulation of hyaluronan in the kidney. Kidney Int 1996, 50:1224-1229.
187. Taylor K.R., Trowbridge J.M., Rudisill J.A., et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004, 279:17079-17084.
188. Porrett P.M., Yuan X., LaRosa D.F., et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol 2008, 181:1692-1699.
189. Thornley T.B., Brehm M.A., Markees T.G., et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. JImmunol 2006, 176:1561-1570.
190. Goldstein D.R. Toll-like receptors and other links between innate and acquired alloimmunity. Curr Opin Immunol 2004, 16:538-544.
191. Andrade C.F., Waddell T.K., Keshavjee S., Liu M. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant 2005, 5:969-975.
192. Goldstein D.R., Tesar B.M., Akira S., Lakkis F.G. Critical role of the toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003, 111:1571-1578.
193. + T cells. Immunology 2007, 122:149-156.
194. Vilaysane A., Chun J., Seamone M.E., et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 2010, 21:1732-1744.
195. Kubo T., Hatton R.D., Oliver J., et al. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 2004, 173:7249-7258.
196. Alegre M., Chen L., Wang T., et al. Antagonistic effect of toll-like receptor signaling and bacterial infections on transplantation tolerance. Transplantation 2009, 87(9 Suppl):S77-S79.
197. Chen L., Wang T., Zhou P., et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006, 6:2282-2291.
198. Walker W.E., Nasr I.W., Camirand G., et al. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 2006, 177:5307-5316.
199. Tesar B.M., Goldstein D.R. Toll-like receptors and their role in transplantation. Front Biosci 2007, 12:4221-4238.
200. Chen L., Ahmed E., Wang T., et al. TLR signals promote IL-6/IL-17-dependent transplant rejection. J Immunol 2009, 182:6217-6225.
201. Wu H., Chen G., Wyburn K.R., et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007, 117:2847-2859.
202. Shigeoka A.A., Holscher T.D., King A.J., et al. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. JImmunol 2007, 178:6252-6258.
203. Goldstein D.R. The identity of innate immune activators in organ transplantation: origins from within or exterior to the host. Am J Transplant 2007, 7:1692-1694.
204. Wells A., Larsson E., Hanás E., et al. Increased hyaluronan in acutely rejecting human kidney grafts. Transplantation 1993, 55:1346-1349.
205. Krüger B., Krick S., Dhillon N., et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A 2009, 106:3390-3395.
206. Pulskens W.P., Teske G.J., Butter L.M., et al. Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. PLoS ONE 2008, 3:e3596.
207. Arumugam T.V., Shiels I.A., Woodruff T.M., Granger D.N., Taylor S.M. The role of the complement system in ischemia-reperfusion injury. Shock 2004, 21:401-409.
208. Zhang H., Qin G., Liang G., et al. C5aR-mediated myocardial ischemia/reperfusion injury. Biochem Biophys Res Commun 2007, 357:446-452.
209. Chávez-Cartaya R.E., DeSola G.P., Wright L., Jamieson N.V., White D.J. Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion. Transplantation 1995, 59:1047-1052.
210. Baldwin W.M., Pruitt S.K., Brauer R.B., Daha M.R., Sanfilippo F. Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation 1995, 59:797-808.
211. De Vries B., Matthijsen R.A., Wolfs T.G., Van Bijnen A.A., Heeringa P., Buurman W.A. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 2003, 75:375-382.
212. Vakeva A.P., Agah A., Rollins S.A., et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998, 97:2259-2267.
213. Ferraresso M., Macor P., Valente M., et al. Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. Transplantation 2008, 86:1445-1451.
214. Glynne P.A., Evans T.J. Inflammatory cytokines induce apoptotic and necrotic cell shedding from human proximal tubular epithelial cell monolayers. Kidney Int 1999, 55:2573-2597.